In April, 23andMe released the Hereditary Amyloidosis (TTR-Related) Genetic Health Risk report* to eligible customers who have opted into receiving health reports. This report looks for 3 variants (V122I, V30M, and T60A) in the TTR gene.
Available now is an on-demand walkthrough of the Hereditary Amyloidosis (TTR-Related) report. Sample reports for the different possible outcomes are located under the reports tab on our site. By watching this recording, you will learn about our Genetic Health Risk reports, get an overview and walkthrough of the Hereditary Amyloidosis (TTR-Related) report, and learn about resources available for healthcare professionals.
This report-walkthrough is intended for healthcare professionals.
Kayla Capper is a Product Scientist at 23andMe where she evaluates scientific literature and writes content for the 23andMe health product. She helped develop the Hereditary Amyloidosis (TTR-Related) Genetic Health Risk report as well as other health reports and features. Kayla earned a PhD in Cancer Biology at the University of Michigan.
*The 23andMe PGS test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. The TTR-related hereditary amyloidosis genetic health risk report is indicated for reporting of V122I, V30M, and T60A variants in the TTR gene and describes if a person has variants associated with an increased risk of developing TTR-related hereditary amyloidosis. The majority of the variants included in this report have been most studied in people of African Americans, West African, Portuguese, Northern Swedish, Japanese, Irish, and British descent.